Partners · Grants · Investors
Backed by leading innovation programs and strategic partners.
AtG’s R&D is co-financed by competitive public funding programmes, backed by strategic investors with operating experience in pharma and MedTech, and carried out in collaboration with leading clinical, academic and technology organisations.
Grants & public funding
Supporting AtG’s path to clinical development.
AtG’s development has been supported by competitive public funding, innovation programs and private investors helping advance its therapeutic and biomarker programs.
9
PROJECTS
3M €
PUBLIC FUNDING
2022-2026
FUNDING PERIOD
AGENCIA ESTATAL DE INVESTIGACIÓN | 97K €
Grant for the hiring of research staff.
GENERALITAT DE CATALUNYA | 22K €
Industrial doctorate research program.
CDTI | 325K €
AtG's individual project to validate the TACTIC platform and advance towards a new precision therapy for advanced solid tumors.
MINISTERIO DE CIENCIA E INNOVACIÓN | 325K €
Photonic sensing and microfluidic monitoring of cancer treatments.
Agencia Estatal de investigación | 501K €
Research program in hepatocellular carcinoma.
Agencia Estatal de investigación | 626K €
Public-private collaboration project to develop a targeted therapy against metabolically adapted tumors.
CDTI · Eureka Network · European Commission | 378K €
AtG coordinates the Eurostars NIAC consortium, developing a new intracellular approach against renal cancer resistant to anti-angiogenic therapies.
Agencia Estatal de investigación | 910K €
Exact title and consortium pending documentary confirmation.
Generalitat de Catalunya — Departament d'Empresa i Treball | 122K €
Generalitat grant to reduce the gender gap in the ICT field, financing the development of advanced ICT solutions.
Public bodies behind our grants.
AtG gratefully acknowledges the public institutions that co-finance our R&D. Their logos are displayed here as a formal acknowledgment of their support.
CDTI
Spanish public agency for national innovation grants (NEOTEC).
EU
European Commission — co-financier of Eurostars via Horizon Europe and NextGenerationEU.
MICINN
Spanish Ministry of Science, Innovation and Universities.
GENCAT
Government of Catalonia — institutional support for R&D.
PRTR
Spain’s Recovery, Transformation and Resilience Plan (NextGenerationEU).
Our investors
A syndicate with operating experience.
AtG is backed by a syndicate of strategic biotech investors and public-backed instruments. Current cap table combines operating executives from pharma and MedTech with patient, long-horizon capital aligned with our multi-year R&D trajectory.
01
STRATEGIC INVESTOR
BGC
BGC backs AtG’s seed round with strategic capital and market-access expertise across European biotech, complementing the company’s scientific founding team with financial and corporate-development firepower.
02
WOMEN ANGELS SYNDICATE
WA4STEAM
Women Angels for STEAM — the first female angel-investment syndicate in Spain, funding women-led deep-tech and life-science ventures. WA4STEAM’s investment in AtG reinforces the company’s commitment to female leadership in oncology biotech.
03
VENTURE INVESTOR
INVENIAM
Inveniam is an early-stage venture investor supporting AtG’s translational oncology platform with capital and operational know-how, helping bridge the path from target validation to IND-filing.
Strategic partners
Clinical, academic and technology partners.
AtG’s work is carried out in close collaboration with leading clinical, academic and technology organisations — the consortium behind our grants and translational milestones.
CLINICAL
Institut Català d'Oncologia
Barcelona, Spain
Leading oncology network in Catalonia. Clinical partner for AtG’s biomarker validation and translational studies in renal, colorectal and hepatocellular carcinoma.
Research
Institut d'Investigació Biomèdica de Bellvitge
L’HOSPITALET DE LLOBREGAT, SPAIN
Biomedical research institute affiliated with ICO and Bellvitge Hospital. Collaborates with AtG on preclinical pharmacology and translational biomarker work for the TACTIC platform.
RESEARCH / TECHNOLOGY
Leitat Technological Center
Terrassa, Spain
Technology centre specialised in advanced materials, biotechnology and process development. AtG’s partner for CMC, analytical development and process scale-up activities.
Academic
Universität Bern
BERN, SWITZERLAND
Swiss university partner in the Eurostars consortium. Contributes medicinal chemistry and structural biology expertise to AtG’s TA-1 lead optimisation programme.
Outsmarting tumor adaptation – together.
Help us advance a new therapeutic strategy for treatment-resistant cancer.